Nefrocarnit (Levocarnitine)

Levocarnitine, the active ingredient in Nefrocarnit, is a Carnitine supplement presented as an intravenous solution for use in patients with carnitine deficiency and related metabolic disorders. It helps restore normal carnitine levels and supports fatty‑acid oxidation in the mitochondria.

GNH USA supplies Nefrocarnit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide, providing reliable sourcing, regulatory compliance, and global logistics to meet clinical demand.

Nefrocarnit is used to treat conditions associated with impaired carnitine metabolism.

- Primary carnitine deficiency: restores systemic carnitine levels and improves energy production. - Secondary carnitine deficiency: compensates for loss of carnitine due to renal disease or medication effects. - Metabolic disorders requiring carnitine supplementation: enhances mitochondrial fatty‑acid β‑oxidation and reduces accumulation of toxic metabolites.

Adverse reactions to intravenous levocarnitine may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Vomiting: occasional episodes during infusion. - Headache: transient discomfort. - Flushing: skin redness and warmth.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Seizures: rare neurologic events observed in susceptible patients. - Cardiac arrhythmia: irregular heart rhythm that may be life‑threatening.

When using Nefrocarnit, clinicians should consider several safety measures.

- Renal impairment: monitor renal function and adjust therapy as needed. - Cardiac disease: observe for arrhythmias and blood pressure changes during infusion. - Pregnancy: use only if potential benefit justifies potential risk to the fetus. - Concomitant medications: review for agents that may alter carnitine levels. - Infusion rate: administer slowly to minimize infusion‑related reactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levocarnitine may interact with certain medicines; awareness of interaction severity is important.

Major Interactions (Avoid): - Valproic acid co‑administration: may increase risk of hyperammonemia. - High‑dose phenobarbital: can accelerate carnitine depletion.

Moderate Interactions (Monitor Closely): - Carbapenem antibiotics: may increase urinary carnitine loss. - Hemodialysis: can remove levocarnitine, reducing efficacy. - Warfarin: monitor INR as carnitine may affect anticoagulant response. - Diuretics: watch electrolyte balance during therapy.